Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06959316 · ClinicalTrials.gov registry record

T1D Pregnancy & Me

A clinical trial of Diabetes Mellitus, Type 1 and Pregnancy, High Risk, sponsored by Jaeb Center for Health Research.

Recruiting
Registry status
500
Enrollment target
10
Study locations

NCT06959316: Recruiting study of Diabetes Mellitus, Type 1 and Pregnancy, High Risk, sponsored by Jaeb Center for Health Research.

NCT06959316 is a study of Diabetes Mellitus, Type 1 and Pregnancy, High Risk that is actively recruiting participants, run by Jaeb Center for Health Research. The registered enrollment target is 500 participants, below the 1,262-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (60% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06959316, a study of Diabetes Mellitus, Type 1 and Pregnancy, High Risk, is actively recruiting participants, sponsored by Jaeb Center for Health Research.

RECRUITING
Registry status
500 participants
Enrollment target
10
Study locations

Study Summary

T1D Pregnancy \& Me will partner with pregnant participants living with type 1 diabetes (T1D) in the United States to collect real-world data on management of T1D in pregnancy. This is a remote study where participants can complete online surveys and share device data (continuous glucose monitor (CGM) data and insulin data). Through the collection of CGM, insulin, and pregnancy outcome data, the study will provide important information to understand how diabetes is being managed during pregnancy. These data will provide much needed evidence to guide modern management of diabetes during pregnancy with a goal of improving care and outcomes.

Primary Outcome

Percentage of time spent with glucose 63-140 mg/dl

Conditions Studied

Diabetes Mellitus, Type 1 Pregnancy, High Risk Insulin Dependent Diabetes Pregnancy in Diabetics

Interventions

  • DEVICE Hybrid closed loop insulin delivery system

Study Locations (10)

Massachusetts

  • Mass General Brigham - Boston
  • Joslin Diabetes Center - Boston

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • Barbara Davis Center for Diabetes & University of Colorado Health - Aurora

Florida

  • Jaeb Center for Health Research - Tampa

Indiana

  • Indiana University - Indianapolis

New York

  • Icahn School of Medicine at Mount Sinai - New York

Ohio

  • The Ohio State University - Columbus

Oregon

  • Oregon Health and Science University - Portland

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2025-04-25
Est. Completion 2027-04
Jaeb Center for Health Research

119 total trials

What NCT06959316 shows while recruiting

NCT06959316 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,262-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (60% lower).

The record links to 4 conditions, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Hybrid closed loop insulin delivery system is the first listed.

NCT06959316 lists 10 locations in 9 states (Massachusetts, Alabama, Colorado).

Frequently Asked Questions

What is clinical trial NCT06959316 about?

NCT06959316 is a clinical study titled "T1D Pregnancy & Me". T1D Pregnancy \& Me will partner with pregnant participants living with type 1 diabetes (T1D) in the United States to collect real-world data on management of T1D in pregnancy. This is a remote study where participants can complete online surveys and share device data (continuous glucose monitor (CG...

What is the current status of trial NCT06959316?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-04-25. Estimated completion is 2027-04.

What conditions does trial NCT06959316 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 1, Pregnancy, High Risk, Insulin Dependent Diabetes, Pregnancy in Diabetics.

What interventions are being tested in trial NCT06959316?

The interventions under investigation include: Hybrid closed loop insulin delivery system (DEVICE).

Who is sponsoring clinical trial NCT06959316?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06959316 being conducted?

This trial has 10 study locations across Alabama, Colorado, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06959316's enrollment target sits among peer trials

500 15th of 118 higher than 104 of 118 other Diabetes Mellitus, Type 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06959316

Source: ClinicalTrials.gov NCT06959316, the US trial registry maintained by the National Library of Medicine. NCT06959316 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.